Condensed Consolidated Statements of Cash Flows - USD ($)	3 Months Ended		9 Months Ended
	Sep. 30, 2024	Sep. 30, 2023	Sep. 30, 2024	Sep. 30, 2023
Cash flows from operating activities:
Net loss			$ (10,063,912)	$ (10,843,502)
Adjustments to reconcile net loss to net cash used in operating activities:
Depreciation and amortization			16,890	2,066
Stockbased compensation			363,408	361,598
Foreign currency (gain) loss	$ 35,494	$ 2,880	(15,180)	(39,686)
Changes in operating assets and liabilities:
Prepaid expenses and other current assets			398,531	1,077,138
Accounts payable			(515,964)	21,873
Accrued expenses			299,387	982,563
Deferred grant revenue			(528,974)
Net cash used in operating activities			(10,045,814)	(8,437,950)
Cash flows from investing activities:
Purchases of property and equipment			(15,478)	(85,943)
Net cash used in investing activities			(15,478)	(85,943)
Cash flows from financing activities:
Proceeds from issuance of common stock			15,999,598	5,788,918
Common stock issuance costs			(1,312,108)	(648,928)
Net cash provided by financing activities			14,687,490	5,139,990
Change in cash and cash equivalents and restricted cash			4,626,198	(3,383,903)
Effect of exchange rate changes on cash, cash equivalents and restricted cash			17,427	(8,782)
Cash, cash equivalents and restricted cash-beginning of year			21,647,537	28,786,647
Cash, cash equivalents and restricted cash-end of period	26,291,162	25,393,962	26,291,162	25,393,962
Reconciliation of cash, cash equivalents and restricted cash
Cash and cash equivalents	26,249,625	25,353,513	26,249,625	25,353,513
Restricted cash	41,537	40,449	41,537	40,449
Total cash, cash equivalents and restricted cash	$ 26,291,162	$ 25,393,962	$ 26,291,162	$ 25,393,962